Stock A357230 H.PIO CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings H.PIO Co., Ltd.

Equities

A357230

KR7357230002

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 16/05/2024 BST 		5-day change 1st Jan Change
3,730 KRW -0.13% Intraday chart for H.PIO Co., Ltd. -6.16% -4.36%
03-20 H.PIO Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Tranche Update on H.PIO Co., Ltd.'s Equity Buyback Plan announced on November 17, 2023. CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The stock, which is currently worth 2024 to 590.63 times its sales, is clearly overvalued in comparison with peers.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company is not the most generous with respect to shareholders' compensation.
  • Revenue estimates are regularly revised downwards for the current and coming years.

Ratings chart - Surperformance

Sector: Food Processing

1st Jan change Capi. Investor Rating ESG Refinitiv
H.PIO CO., LTD. Stock H.PIO Co., Ltd.
-4.36% 112M -
ZHEJIANG NHU COMPANY LTD. Stock Zhejiang NHU Company Ltd.
+16.86% 8.48B
D+
BELLRING BRANDS, INC. Stock BellRing Brands, Inc.
+6.26% 7.6B
C-
CSPC INNOVATION PHARMACEUTICAL CO., LTD. Stock CSPC Innovation Pharmaceutical Co., Ltd.
+4.89% 6.39B -
THE SIMPLY GOOD FOODS COMPANY Stock The Simply Good Foods Company
-5.76% 3.75B
B-
BYHEALTH CO., LTD Stock Byhealth Co., Ltd
-6.58% 3.71B
D
XIAMEN KINGDOMWAY GROUP COMPANY Stock Xiamen Kingdomway Group Company
-3.55% 1.36B - -
HERBALIFE LTD. Stock Herbalife Ltd.
-27.65% 1.11B
B+
SIRIO PHARMA CO., LTD. Stock Sirio Pharma Co., Ltd.
+18.12% 1.02B -
USANA HEALTH SCIENCES, INC. Stock USANA Health Sciences, Inc.
-8.92% 924M
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
  1. Stock Market
  2. Equities
  3. A357230 Stock
  4. Ratings H.PIO Co., Ltd.